Key regions: Australia, Germany, United Kingdom, United States, France
The demand for Immunosuppressants in Turkey has been increasing steadily in recent years.
Customer preferences: The increasing prevalence of autoimmune diseases and organ transplantation procedures has been the driving force behind the growth of the Immunosuppressants market in Turkey. Patients suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis require long-term medication to manage their symptoms. Similarly, organ transplant recipients need to take Immunosuppressants to prevent their body from rejecting the transplanted organ.
Trends in the market: The Immunosuppressants market in Turkey is dominated by branded drugs, with a few generic alternatives available. However, the government's efforts to promote the use of generic drugs are expected to increase the market share of generic Immunosuppressants in the coming years. Additionally, the market is witnessing a shift towards biologic Immunosuppressants, which offer better efficacy and safety profiles compared to traditional Immunosuppressants.
Local special circumstances: Turkey's healthcare system is a mix of public and private providers, with the government providing universal healthcare coverage to its citizens. However, the system is underfunded, and patients often have to pay out of pocket for expensive medications such as Immunosuppressants. This has led to a growing demand for affordable generic drugs, which is expected to drive the growth of the generic Immunosuppressants market in the country.
Underlying macroeconomic factors: Turkey's pharmaceutical market is one of the largest in the Middle East and North Africa (MENA) region, with a rapidly growing population and increasing healthcare expenditure. Additionally, the country's strategic location makes it an attractive market for pharmaceutical companies looking to expand their presence in the region. However, the market is highly regulated, with the government setting price controls on drugs and limiting the reimbursement of expensive medications. This has led to a challenging business environment for pharmaceutical companies operating in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
